Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
#TradFi交易分享挑战 MRNA Price Trend Analysis:
As of May 28, 2026, Moderna (stock code: MRNA) stock price is $46.88, down 0.80% from the previous trading day. The day's price fluctuation range was $46.77 to $48.35, with a trading volume of approximately 4.22M shares and a turnover rate of 1.06%. Recently, the stock price has shown volatility influenced by clinical data on tumor vaccines, progress in flu vaccines, and financial performance. It is recommended to monitor the company's upcoming clinical data releases and business developments, and to make cautious decisions.
1 Recent Volatility
Recent stock price fluctuations have been significant, with amplitude around 4.5%-5%, and trading volume has increased, indicating heightened market attention.
2 Long-term Trend Changes
From a peak market value of about $195.5 billion in 2021 to a historical low of $22.28 in November 2025, the decline exceeds 95%, with market value shrinking to less than $12 billion.
Since early 2026, the stock price has rebounded but has not yet recovered to pre-pandemic levels, currently in the $48-$49 range, about 75% below the peak.
3 Analysis of Influencing Factors
Positive factors:
COVID-19 vaccines (such as MNEXSPIKE) approved in multiple countries, increasing international market demand, driving revenue growth.
Progress in tumor treatments (like mRNA-4157) and rare disease drug development, boosting market expectations for the company's future potential.
Negative factors:
Demand for COVID-19 vaccines wanes, traditional vaccine markets are saturated, and new vaccines (such as RSV vaccine MRESVIA) sales have not met expectations.
High R&D investment and ongoing cost pressures, with the company still operating at a loss, reporting a net loss of $1.34B in Q1 2026.
Moderna's stock price has recently rebounded due to vaccine business recovery and R&D progress, but long-term challenges remain, including demand fluctuations, cost pressures, and market competition. Breakthroughs in tumor and rare disease drug development could further boost the stock price; if new vaccine markets do not expand well or cost control is poor, the stock price may face renewed pressure.
As of May 28, 2026, Moderna (stock code: MRNA) stock price is $46.88, down 0.80% from the previous trading day. The day's price fluctuation range was $46.77 to $48.35, with a trading volume of approximately 4.22M shares and a turnover rate of 1.06%. Recently, the stock price has been influenced by factors such as clinical data for tumor vaccines, progress in flu vaccines, and financial performance, showing volatile movements. It is recommended to pay attention to the company's subsequent clinical data releases and business developments, and to make cautious decisions.
1 Recent Volatility
Recent stock price fluctuations are relatively large, with an amplitude of about 4.5%-5%, and trading volume has increased, indicating heightened market attention.
2 Long-term Trend Changes
From a peak market value of approximately $195.5 billion in 2021 to a historical low of $22.28 in November 2025, the decline exceeds 95%, with market value shrinking to less than $12 billion.
Since the beginning of 2026, the stock price has rebounded but has not yet recovered to pre-pandemic levels, currently in the $48-$49 range, still about 75% below the peak.
3 Analysis of Influencing Factors
Positive Factors:
COVID-19 vaccines (such as MNEXSPIKE) approved in multiple countries, increasing international market demand, driving revenue growth.
Progress in tumor treatments (such as mRNA-4157) and rare disease drug development, enhancing market expectations for the company's future potential.
Negative Factors:
Decline in COVID-19 demand, saturation of traditional vaccine markets, and underperformance of new vaccines (such as RSV vaccine MRESVIA).
Ongoing high R&D investment and cost pressures, with the company still operating at a loss, reporting a net loss of $1.34B in Q1 2026.
Moderna's stock price has recently rebounded due to vaccine business recovery and R&D progress, but long-term challenges remain in demand fluctuations, cost pressures, and market competition. Breakthroughs in tumor and rare disease drug development could further boost the stock price; if new vaccine market expansion falters or cost control is poor, the stock price may face renewed pressure.